Filing Analysis
Turn Therapeutics Inc. announced that GEM Yield Bahamas Limited has fully exercised a warrant to acquire 579,664 shares of common stock via a cashless exercise. This follows a previous warrant issuance from October 2025, representing a portion of the company's fully diluted shares.
🚩 Red Flags
- Dilution: The issuance of 579,664 shares via cashless exercise increases the total share count without an immediate influx of cash to the company.
📋 Key Facts
- Date of event: August 13, 2026
- Warrant holder: GEM Yield Bahamas Limited
- Shares issued: 579,664 shares of Common Stock
- Exercise method: Cashless Exercise Provision
- Original warrant size: 1,192,207 shares (representing 4% of fully diluted shares as of Oct 8, 2025)
- Exemption used: Section 4(a)(2) of the Securities Act of 1933 (Accredited Investor)
Turn Therapeutics Inc. entered into securities purchase agreements on August 14, 2026, to issue and sell 135,000 shares of common stock to existing series and seed investors. The private placement raised aggregate gross proceeds of $1.35 million at a price of $10.00 per share.
🚩 Red Flags
- Small capital raise ($1.35M) suggests limited liquidity runway for a micro-cap company.
- Reliance on existing seed/series investors for capital often indicates difficulty in attracting new institutional capital.
📋 Key Facts
- Date of event: August 14, 2026
- Total shares issued: 135,000 shares of common stock
- Price per share: $10.00
- Aggregate gross proceeds: $1.35 million
- Investors: Existing series and seed investors (accredited investors)
- The offering was conducted via private placement under Section 4(a)(2) of the Securities Act of 1933.
- The Company granted registration rights to the Investors regarding the newly issued shares.
Turn Therapeutics Inc. filed an 8-K to announce its financial and operating results for the quarter ended June 30, 2026. The filing serves as a formal notification of the earnings release issued on August 12, 2026.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 12, 2026.
- The company is an emerging growth company.
- Results are furnished via a press release (Exhibit 99.1) rather than being formally 'filed' under Section 18 of the Exchange Act.
Turn Therapeutics Inc. has released an updated investor presentation as of July 28, 2026. This filing is a routine disclosure under Item 7.01 to provide supplemental information to the market.
📋 Key Facts
- The company released an updated Investor Presentation on July 28, 2026.
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
- The registrant is classified as an emerging growth company.
Turn Therapeutics Inc. filed an 8-K to furnish a press release and an updated investor presentation issued on July 7, 2026.
📋 Key Facts
- The company released a Press Release (Exhibit 99.1) on July 7, 2026.
- The company released an updated Investor Presentation (Exhibit 99.2) on July 7, 2026.
- Information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Turn Therapeutics Inc. filed an 8-K to furnish an updated investor presentation released on June 1, 2026. The filing serves as a formal disclosure of information shared with investors to ensure compliance with Regulation FD.
📋 Key Facts
- The company released an updated investor presentation on June 1, 2026.
- The presentation is attached as Exhibit 99.1.
- The filing was signed by CEO Bradley Burnam on June 3, 2026.
Turn Therapeutics Inc. filed an 8-K to furnish a press release issued on June 1, 2026. The filing serves as a formal disclosure of information under Regulation FD.
📋 Key Facts
- The filing date is June 1, 2026.
- The company furnished a press release as Exhibit 99.1.
- The information is provided under Item 7.01 (Regulation FD Disclosure), meaning it is 'furnished' rather than 'filed' for Section 18 liability purposes.
Turn Therapeutics Inc. filed an 8-K to furnish a press release issued on May 27, 2026. The filing is specifically categorized under Item 7.01, meaning the information is furnished rather than filed, and the company explicitly states that the information is not subject to the liabilities of Section 18 of the Exchange Act.
📋 Key Facts
- The filing date is May 27, 2026.
- The company is an 'Emerging Growth Company'.
- The primary purpose of is to furnish a press release (Exhibit 99.1).
- The information is furnished under Item 7.01 (Regulation FD Disclosure).
Turn Therapeutics Inc. filed a Form 8-K on May 19, 2026, to disclose a press release under Regulation FD. The specific contents of the press release were not detailed in the main body of the filing.
📋 Key Facts
- Turn Therapeutics Inc. issued a press release on May 19, 2026.
- The press release was furnished as Exhibit 99.1 under Item 7.01.
- The filing was signed by Bradley Burnam, Chief Executive Officer.
Turn Therapeutics Inc. issued a press release on May 18, 2026, which was furnished to the SEC under Regulation FD disclosure requirements.
📋 Key Facts
- The company issued a press release on May 18, 2026.
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- Exhibit 99.1 contains the full text of the press release.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Turn Therapeutics Inc. announced its financial and operating results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02.
- Turn Therapeutics is classified as an emerging growth company.
- The company is listed on The Nasdaq Stock Market LLC under the ticker TTRX.
Turn Therapeutics Inc. announced its financial and operating results for the fiscal year ended December 31, 2025, via a press release furnished with the filing.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release was issued and the 8-K filed on March 31, 2026.
- The company is classified as an emerging growth company.
Turn Therapeutics entered into a $25 million loan and security agreement with Avenue Venture Opportunities Fund II, L.P., securing an initial $7 million tranche. The debt is high-cost, secured by all company assets including intellectual property, and includes significant dilutive components such as an upfront equity grant and a discounted conversion option.
🚩 Red Flags
- High interest rate (minimum 12.25%) relative to traditional corporate debt.
- Significant dilution risk from the $1.2M upfront equity grant and the 20% discount on the debt conversion option.
- All intellectual property is pledged as collateral, creating high risk in the event of default.
- Future funding tranches are conditional on milestones, which may create liquidity pressure if clinical trials face delays.
📋 Key Facts
- Total loan facility of up to $25.0 million across three tranches, with $7.0 million funded immediately.
- Interest rate is the greater of (Prime + 5.50%) or 12.25% per annum.
- The loan is secured by a lien on all company assets, including intellectual property.
- Issued $1.2 million in common stock to the lender as an upfront equity grant.
- Lender has a conversion option for up to $3.0 million of principal at a 20% discount to the market price (80% of closing price).
- Tranches 2 ($8M) and 3 ($10M) are contingent upon clinical and financing milestones.
- Maturity date is set for October 1, 2029, with a final payment fee of 3.75% of the total funded amount.
Turn Therapeutics Inc. filed an 8-K to furnish a press release issued on February 17, 2026, under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or operational data beyond the notification of the press release.
📋 Key Facts
- Filed on February 17, 2026
- The company is an emerging growth company
- The filing serves to furnish a press release (Exhibit 99.1) under Regulation FD Disclosure
- No specific financial figures or material changes were disclosed in the text of the 8-K itself
Turn Therapeutics Inc. issued an 8-K to announce upcoming presentations at healthcare conferences and the release of an updated investor presentation.
📋 Key Facts
- The company issued a press release on February 9, 2026, regarding upcoming healthcare conference presentations (Exhibit 99.1).
- An updated investor presentation was posted to the company website on February 9, 2026 (Exhibit 99.2).
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liability.
Turn Therapeutics Inc. filed an 8-K to furnish a press release dated January 12, 2026, under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or operational data beyond the notification of the press release.
📋 Key Facts
- Filing date: January 12, 2026
- The company is an emerging growth company.
- The filing consists solely of a cover page and a reference to Exhibit 99.1 (Press Release).
- No specific financial results or material agreements were disclosed in the text provided.
Turn Therapeutics Inc. has expanded its Board of Directors by appointing Martin Dewhurst as an independent Class III director and Chair of the Compensation Committee.
📋 Key Facts
- Board size increased from five to six members effective January 7, 2026.
- Martin Dewhurst appointed as an independent Class III director.
- Mr. Dewhurst will serve as the chair of the compensation committee.
- Initial equity grant: $100,000 in Restricted Stock Units (RSUs) under the 2025 Omnibus Incentive Plan.
- RSU vesting schedule: One year from grant date or upon a change of control.
- Future compensation: Eligible for annual RSU grants with a fair value of $70,000 following the company's direct listing.
Turn Therapeutics Inc. filed an 8-K to announce its financial and operating results for the quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing financial and operating results.
- Company is an emerging growth company.
Turn Therapeutics Inc. filed an 8-K to furnish two press releases issued on November 11, 2025. The filing does not contain substantive financial data or material event disclosures within the text itself.
🚩 Red Flags
- No substantive information provided in the text; actual material content is contained in external exhibits not fully detailed here.
📋 Key Facts
- The company issued two press releases dated November 11, 2025 (Exhibits 99.1 and 99.2).
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and Item 9.01.
- The company is an emerging growth company.
Turn Therapeutics Inc. filed an 8-K to furnish a press release dated November 4, 2025, under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or operational data beyond the announcement of the press release.
📋 Key Facts
- The company issued a press release on November 4, 2025.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Turn Therapeutics Inc. filed an 8-K to furnish a press release dated October 30, 2025, under Item 7.01 (Regulation FD Disclosure). The filing itself contains no substantive financial or operational data beyond the notification of the press release.
🚩 Red Flags
- No substantive information provided in the 8-K text; actual news is contained in the unprovided Exhibit 99.1.
📋 Key Facts
- Filing date: October 30, 2025
- The company is an emerging growth company.
- The filing serves to furnish a press release as Exhibit 99.1 under Item 7.01.
Turn Therapeutics entered into a Global Supply, Development, and License Agreement with Medline Industries, LP to commercialize products using Turn's PermaFusion® platform. The partnership leverages Medline's massive global distribution network for professional and retail markets.
📋 Key Facts
- Agreement signed on October 27, 2025, with Medline Industries, LP.
- Medline will lead global commercialization and distribution in over 100 countries/territories.
- Turn provides formulation expertise, IP, and clinical development capabilities.
- The agreement has an initial term of three years with automatic one-year renewals.
- Focus is on manufacturing scale-up and co-branding for PermaFusion-based products.
Turn Therapeutics Inc. filed an 8-K to furnish a press release dated October 22, 2025. The filing does not contain substantive financial data or material event disclosures within the text provided.
📋 Key Facts
- Filing date: October 22, 2025
- The company is an emerging growth company.
- The filing consists of a cover page and an exhibit (99.1) containing a press release.
Turn Therapeutics Inc. announced the SEC's effectiveness of its Form S-1 registration statement for a direct listing on the Nasdaq Global Market. The filing details several material agreements with founder Bradley Burnam and the appointment of new independent directors.
🚩 Red Flags
- Related-party transactions: The company entered into Stockholders Agreement and Registration Rights Agreements with the founder (Bradley Burnam) and his entity (BEB Holdings, LLC).
- Control concentration: The Stockholders Agreement requires consent from the Holders for certain corporate actions.
📋 Key Facts
- SEC declared effective the Form S-1 registration statement on September 30, 2025.
- The company is pursuing a direct listing on the Nasdaq Global Market.
- Up to 17,868,760 shares of Common Stock may be offered or sold via the direct listing.
- Entered into a Stockholders Agreement and Registration Rights Agreement with founder Bradley Burnam and BEB Holdings, LLC.
- Arthur Golden and Dr. Kent Kester appointed to the Board of Directors on September 30, 2025.
- Amended and restated Certificate of Incorporation and Bylaws became effective as of September 30, 2025.